For the Inventor, By the Inventor

Enter assignee name

Raleigh, NC, United States of America

Liposcience, Inc.

USPTO Granted Patents = 35

% Expired Patents = 8.6

CIPO Patents = 3

EPO Patents = 12

Trademarks = 5

Forward Citations = 226

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

James D Otvos (33 out of 41 patents)

Irina Y Shalaurova (18 out of 21 patents)

Elias J Jeyarajah (11 out of 12 patents)

4. Dennis W Bennett (11 out of 14 patents)

5. Justyna E Wolak-Dinsmore (10 out of 11 patents)

6. Thomas M O'Connell (8 out of 8 patents)

7. Steven P Matyus (7 out of 7 patents)

8. David R Morgan (5 out of 5 patents)

9. Stephen Markham (4 out of 4 patents)

10. Bruce D Silberman (4 out of 4 patents)

11. Donald R Deuel (4 out of 4 patents)

12. Kelly Mercier (4 out of 4 patents)

13. Stanley Leon Hazen (3 out of 59 patents)

14. Stanley L Hazan (1 out of 1 patent)

15. Russell Reeve (1 out of 1 patent)

35 patents: Sort by Forward Citations

1. 12130295 - NMR system and methods for multi-parameter metabolic vulnerability index evaluations (2024-10-29),

2. 11990243 - Multiple-marker risk parameters predictive of conversion to diabetes (2024-05-21),

3. 11988679 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2024-05-21),

4. 11942187 - Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements (2024-03-26),

5. 11782002 - NMR quantification of TMAO (2023-10-10),

6. 11710568 - Multi-parameter diabetes risk evaluations (2023-07-25),

7. 11703501 - CHD risk stratification evaluations for subjects with high levels of large HDL-P (2023-07-18),

8. 11231429 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2022-01-25),

9. 11156685 - NMR analyzers for clinical evaluation of biosamples (2021-10-26),

10. 11156621 - Multi-parameter metabolic vulnerability index evaluations (2021-10-26),

11. 11037683 - Multiple-marker risk parameters predictive of conversion to diabetes (2021-06-15),

12. 10852293 - NMR measurements of NMR biomarker GlycA (2020-12-01),

13. 10613044 - NMR quantification of TMAO (2020-04-07),

14. 10504610 - Methods, systems and computer programs for assessing CHD risk using adjusted HDL article number measurements (2019-12-10),

15. 10388414 - Multi-parameter diabetes risk evaluations (2019-08-20),

Liposcience, Inc. is a medical technology company focused on the development and commercialization of blood tests for cardiovascular diseases. Their primary product, the NMR LipoProfile® test, measures the number and size of lipoprotein particles to provide better insights into cardiovascular risk assessment. Liposcience's innovative technology allows for accurate and comprehensive lipid testing, helping healthcare professionals in personalized treatment strategies for their patients. With a commitment to improving patient care and outcomes, Liposcience continues to advance the field of cardiovascular diagnostics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Liposcience, Inc.

35 Patents

#23 in Raleigh, NC

#230 in North Carolina

#9,730 in US

#19,119 in the World

Raleigh, NC, United States of America

Liposcience, Inc.

Forward Citations = 226

15 inventors:

James D Otvos (33 out of 41 patents)

Irina Y Shalaurova (18 out of 21 patents)

Elias J Jeyarajah (11 out of 12 patents)

4. Dennis W Bennett (11 out of 14 patents)

5. Justyna E Wolak-Dinsmore (10 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…